Brief: Enlivex Receives Positive Dsmb Recommendation And Imoh Clearance To Continue Phase I/Ii Trial Of Allocetra Combined With Chemotherapy In Patients With Peritoneal Metastases Arising From Solid Cancers
20/03/2023 12:40
March 20 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX RECEIVES POSITIVE DSMB RECOMMENDATION AND IMOH
CLEARANCE
TO CONTINUE PHASE I/II TRIAL OF ALLOCETRA COMBINED WITH
CHEMOTHERAPY IN PATIENTS WITH PERITONEAL METASTASES ARISING FROM
SOLID CANCERS
* ENLIVEX THERAPEUTICS LTD - THERE WERE NO MORTALITIES NOR
DSMB-IDENTIFIED SAFETY SIGNALS IN FIRST COHORT
Source text for Eikon: ID:nGNX3NrWgw
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment